Emerging drugs for diabetic foot ulcers

Expert Opinion on Emerging Drugs

Volumn 11, Issue 4, 2006, Pages 709-724

  Petrova, Nina ^a   Edmonds, Michael ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Diabetic foot ulcer; Growth factors; Skin substitutes; Wound healing

Indexed keywords

ACTOVEGIN; ADENOSINE RECEPTOR STIMULATING AGENT; BECAPLERMIN; CT 102; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; HYALURONIC ACID; ILOPROST; IMMUNOSTIMULATING AGENT; KETANSERIN; LIPOPROSTAGLANDIN E1; LOW MOLECULAR WEIGHT HEPARIN; NITRIC OXIDE DONOR; PLATELET DERIVED GROWTH FACTOR; PREZATIDE COPPER; PROTEINASE INHIBITOR; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; SULODEXIDE; TELBERMIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

DIABETIC FOOT; FOOT ULCER; GENE THERAPY; HUMAN; HYPERGLYCEMIA; INFECTION; ISCHEMIA; NEUROPATHY; REVIEW; SKIN GRAFT; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING; VACUUM ASSISTED CLOSURE; WOUND HEALING;

DIABETIC FOOT; DRUGS, INVESTIGATIONAL; HUMANS; HYPOGLYCEMIC AGENTS; SKIN, ARTIFICIAL;

EID: 33750956014     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.11.4.709     Document Type: Review

References (106)

1. REIBER GE: Epidemiology of foot ulcers and amputations in the diabetic foot. In: Levin and O'Neal's The Diabetic Foot 6th Edition. Bowker JH, Pfeifer MA (Eds), Mosby, St Louis, USA (2001):13-32.
2. PECORARO RE, REIBER GE, BURGESS EM: Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care (1990) 13:513-521.
3. BAKKER K, FOSTER AVM, VAN HOUTOUM WH et al.: International Diabetes Federation and International Working Group of the Diabetic Foot. Time To Act. The Netherlands (2005).
4. BLAKYTNY R, JUDE E: The molecular biology of chronic wounds and delayed healing in diabetes. Diabet. Med. (2006) 23:594-608.
5. MARGOLIS DJ, ALLEN-TAYLOR L, HOFFSTAD O, BERLIN JA: Healing diabetic neuropathic foot ulcers: are we getting better? Diabet. Med. (2005) 22:172-176.
6. PARKHOUSE N, LE QUESNE PM: Impaired neurogenic vascular response in patients with diabetes and neuropathic foot lesions. N. Engl. J. Med. (1988) 318:1306-1309.
7. ARONIN N, LEEMAN SL, CLEMENTS RS: Diminished flare response in neuropathic diabetic patients: comparison of effects of substance P, histamine, and capsaicin. Diabetes (1987) 36:1139-1143.
8. RAYMAN G, MALIK RA, SHARMA AK, DAY JL: Microvascular response to tissue injury and capillary ultrastructure in the foot skin Type 1 diabetic patients. Clin. Sci. (1995) 89:467-474.
9. RAYMAN G, HASSAN A, TOOKE JE: Blood flow in the skin of the foot related to posture in diabetes mellitus. BMJ (1986) 292:87-90.
10. EDMONDS ME: The diabetic foot, 2003. Diabetes Metab. Res. Rev. (2004) 20(Suppl. 1):S9-S12.
11. KORZON-BURAKOWSKA A, EDMONDS M: Role of the microcirculation in diabetic foot ulceration. Int. J. Low Extrem. Wounds (2006) 5:144-148.
12. LOGERFO FW, COFFMAN JD: Vascular and microvascular disease of the foot in diabetes; implications for foot care. N. Engl. J. Med. (1984) 311:1615-1619.
13. GOLDENBERG S, MORRIS A, JOSHI RA, BLUMENTHAL HT: Non atheromatous peripheral vascular disease of the lower extremity in diabetes mellitus. Diabetes (1959) 8:261-273.
14. FERRIER TM: Comparative study of arterial disease in amputated lower limbs from diabetics and non-diabetics. Med. J. Aust. (1967) 1:5-11.
15. EDMONDS M: Infection in the neuroischemic foot. Int. J. Low Extrem. Wounds (2005) 4(3):145-153.
16. EDMONDS M, FOSTER AV: Diabetic foot ulcers. BMJ (2006) 332(7538):407-410.
17. BOYKO EJ, AHRONI JH, COHEN V, NELSON KM, HEAGERTY PJ: Prediction of diabetic foot ulcer occurrence using commonly available clinical information: the Seattle Diabetic Foot Study. Diabetes Care (2006) 29(6):1202-1207.
18. HARDING KG, MORRIS HL, PATEL GK: Healing chronic wounds. BMJ (2002) 324:160-163.
19. LEAPER D, PAGGI B, COMPTON GA, ORSTED H, TEOT L, OCKENFELS HM: Growth factors and interactive dressings in wound repair. EMWA J. (2002)2:17-23.
20. BLAKYTNY R, JUDE EB, MARTIN GIBSON J, BOULTON AJ, FERGUSON MW: Lack of insulin-like growth factor 1 (IGF1) in the basal keratinocyte layer of diabetic skin and diabetic foot ulcers. J. Pathol. (2000) 190(5):589-594.
21. DENNIS PA, RIFKIN DB: Cellular activation of latent transforming growth factor β required binding to the cation-independent mannose-6-phosphate/ insulin-like growth Factor II receptor. Proc. Natl. Acad. Sci. USA (1991) 88:580-584.
22. JUDE EB, BLAKYTNY R, BULMER J, BOULTON AJ, FERGUSON MW: Transforming growth factor-beta 1,2,3 and receptor Type I and II in diabetic foot ulcers. Diabet. Med. (2002) 19(6):440-447.
23. JUDE EB, TENTOLOURIS N, APPLETON I, ANDERSON S, BOULTON AJM: Role of neuropathy and plasma nitric oxide in recurrent neuropathic and neuroischaeimic diabetic foot ulcers. Wound Rep. Regen. (2001) 9:353-359.
24. JUDE EB, BOULTON AJM, FERGUSON MWJ, APPLETON I: The role of nitric oxide synthetase isoforms and arginase in the pathogenesis of diabetic foot ulcers: possible modulatory effects by transforming growth factor β1. Diabetologia (1999) 42:748-757.
25. KING L: Impaired wound healing in patients with diabetes. Nurs. Stand. (2001) 15(38):39-45.
26. ALBERTSON S, HUMMEL RP III, BREEDEN M, GREENHALGH DG: PDGF and FGF reverse the healing impairment in protein-malnourished diabetic mice. Surgery (1993) 114:368-372.
27. LOBMANN R, SCHULTZ G, LEHNERT H: Proteases and the diabetic foot syndrome: mechanisms and therapeutic implications. Diabetes Care (2005) 28:461-471.
28. HEHENBERGER K, KRATZ G, HANSSON A, BRISMAR K: Fibroblasts derived from human chronic diabetic wounds have a decreased proliferation rate, which is recovered by the addition of heparin. J. Dermatol. Sci. (1998) 16(2):144-151.
29. HEHENBERGER K, HEILBORN JD, BRISMAR K, HANSSON A: Inhibited proliferation of fibroblasts derived from chronic diabetic wounds and normal dermal fibroblasts created with high glucose is associated with increased formation of L-lactate. Wound Repair Regen. (1998) 6(2):135-141.
30. FERGUSTON MW, HERRICK SE, SPENCER MJ, SHAW JE, BOULTON AJ, SLOAN P: The history of diabetic foot ulcers. Diabet. Med. (1996) 13:S30-S33.
31. DELAMAIRE M, MAUGENDRE D, MORENO M, LE GOFF MC, ALLANIC H, GENETET B: Impaired leucocyte function in diabetic patients. Diabet. Med. (1997) 14:29-34.
32. SPRAVCHIKOV N, SIZYAKOV G, GARTSBEIN M, ACCILI D, TENNENBAUM T, WERTHEIMER E: Glucose effects on skin keratinocytes: implications for diabetes skin complications. Diabetes (2001) 50(7):1627-1635.
33. DURAISAMY Y, SLEVIN M, SMITH N et al.: Effect of glycation on basic fibroblast growth factor induced angiogenesis and activation of associated signal transduction pathways in vascular endothelial cells: possible relevance to wound healing in diabetes. Angiogenesis (2001) 4(4):277-288.
34. EDMON DS M, FOSTER AVM, SANDERS LJ: A practical manual of diabetic foot care. Blackwell Science, Oxford (2004).
35. ARMSTRONG DG, LAVERY LA, WU S, BOULTON AJ: Evaluation of removable and irremovable cast walkers in the healing of diabetic foot wounds: a randomized controlled trial. Diabetes Care (2005) 28(3):551-554.
36. KATZ IA, HARLAN A, MIRANDA-PALMA B et al.: A randomized trial of two irremovable off-loading devices in the management of plantar neuropathic diabetic foot ulcers. Diabetes Care (2005) 28(31:555-559.
37. STEED DL: Foundations of good ulcer care. Am. J. Surg. (1998) 176(Suppl. 2a):20S-25S.
38. GRANICK M, BOYKIN J, GAMELLI R, SCHULTZ G, TENENHAUS M: Toward a common language: surgical wound bed preparation and debridement. Wound Repair Regen. (2006) 14(Suppl. 1):S1-S10.
39. FALANGA V: Wound healing and its impairment in the diabetic foot. Lancet (2005) 366(9498):1736-1743.
40. HILTON JR, WILLIAMS DT, BEUKER B et al.: Wound dressings in diabetic foot disease. Clin. Infect. Dis. (2004) 39(Suppl. 2):S100-S103.
41. MASON JM, O'KEEFE C, MCINTOSH A et al.: A systematic review of foot ulcer in patients with Type 2 diabetes - Part II: treatment. Diab. Med. (1999) 16:889-909.
42. ARMSTRONG DG, LAVERY LA: Diabetic Foot Study Consortium. Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial. Lancet (2005) 366(9498):1704-1710.
43. FAGLIA E, FAVALES F, ALDEGHI A et al.: Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer. A randomized study. Diabetes Care (1996) 19(12):1338-1343.
44. WUNDERLICH RP, PETERS EJ, LAVERY LA: Systemic hyperbaric oxygen therapy: lower-extremity wound healing and the diabetic foot. Diabetes Care (2000) 23(10):1551-1555.
45. CAVANAGH PR, LIPSKY BA, BRADBURY AW et al.: Treatment for diabetic foot ulcers. Lancet (2005) 366(9498):1725-1735.
46. WRIGHT JB, LAM K, BURRELL RE: Wound management in an era of increasing bacterial antibiotic resistance: a role for topical silver treatment. Am. J. infect. Control (1998) 26:572-577.
47. RAYMAN G, RAYMAN A, BAKER NR et al.: Sustained silver-releasing dressing in the treatment of diabetic foot ulcers. Br. J. Nurs. (2005) 14(2):109-114.
48. IP M, LUI SL, POON VKM, LUNG I, BURD A: Antimicrobial activities of silver dressings: an in vitro comparison. J. Med. Microbiol. (2006) 55:59-63.
49. SIGALA F, MENENAKOS C, SIGALAS P et al.: Transluminal angioplasty of isolated crural arterial lesions in diabetics with critical limb ischemia. VASA (2005) 34(3):186-191.
50. MARSTON WA: Risk factors associated with healing chronic diabetic foot ulcers: the importance of hyperglycemia. Ostomy/Wound Management (2006) 52(3):26-28.
51. VILEIKYTE L, RUBIN RR, LEVENTHAL H: Psychological aspects of diabetic neuropathic foot complications: an overview. Diabetes Metab. Res Rev. (2004) 20(1):S13-S18.
52. TSANG MW, WONG WK, HUNG CS et al.: Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care (2003) 26(6):1856-1861.
53. SENET P: Becaplermin gel (Regranex gel). Ann. Dermatol. Venereol. (2004) 131:351-358.
54. STEED DL: Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group. J. Vasc. Surg. (1995) 21(1):71-78; discussion 79-81.
55. WIEMAN TJ, SMIELL JM, SU Y: Efficacy and safety of a topical gel formulation of recombinant human platelet derived growth factor - BB (Becaplermin) in patients with non healing diabetic ulcers: a Phase III, randomized, placebo-controlled, double-blind study. Diabetes Care (1998) 21:822-827.
56. RICHARD JL, PARER-RICHARD C, DAURES JP et al.: Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. A pilot, randomized, double-blind, placebo-controlled study. Diabetes Care (1995) 18:64-69
57. MOTOMURA H, OHASHI N, HARADA T et al.: Aggressive conservative therapy for refractory ulcer with diabetes and/or arteriosclerosis. J. Dermatol. (2006) 33:353-359.
58. GALIANO RD, TEPPER OM, PELO CR et al.: Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am. J. Pathol. (2004) 164(6):1935-1947.
59. KOVEKER GB: Growth factors in clinical practice. Int. J. Clin. Pract. (2000) 54:590-593.
60. MARGOLIS DJ, KANTOR J, SANTANNA J, STROM BL, BERLIN JA: Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers. Diabetes Care (2001) 24(3):483-488.
61. STEED DL, GOSLEN JB, HOLLOWAY GA, MALONE JM, BUNT TJ, WEBSTER MW: Randomized prospective double-blind trial in healing chronic diabetic foot ulcers. CT-102 activated platelet supernatant, topical versus placebo. Diabetes Care (1992) 15(11):1598-604.
62. HARVIMA IT, VIRNES S, KAUPPINEN L et al.: Cultured allogeneic skin cells are effective in the treatment of chronic diabetic leg and foot ulcers. Acta Derm. Venereol. (1999) 79(3):217-220.
63. HAN SK, CHOI KJ, KIM WK: Clinical application of fresh fibroblast allografts for the treatment of diabetic foot ulcers: a pilot study. Plast. Reconstr. Surg. (2004) 114:1783-1789.
64. MOUSTAFA M, SIMPSON C, GLOVER M et al.: A new autologous keratinocyte dressing treatment for non-healing diabetic neuropathic foot ulcers. Diabet. Med. (2004) 21:786-789.
65. BREM H, YOUNG J, TOMIC-CANIC M, ISAACS C, EHRLICH HP: Clinical efficacy and mechanism of bilayered living human skin equivalent (HSE) in treatment of diabetic foot ulcers. Surg. Technol. Int. (2003) 11:23-31.
66. TAUSCHE AK, SKARIA M, BOHLEN L et al.: An autologous epidermal equivalent tissue-engineered from follicular outer root sheath ketatinocytes is as effective as split-thickness skin autograft in recalcitrant vascular leg ulcers. Wound Repair Regen. (2003) 11:248-252.
67. GENTZKOW GD, IWASAKI SD, HERSHON KS et al.: Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care (1996) 19:350-354.
68. EDMONDS ME, FOSTER AVM, MCCOLGAN M: Dermagraft: a new treatment for diabetic foot ulcers. Diabet. Med. (1997) 14:1010-1011.
69. NAUGHTON G, MANSBRIDGE J, GENTZKOW G: A metabolically active human dermal replacement for the treatment of diabetic foot ulcers. Artificial Organs (1997) 21:1203-1210.
70. MARSTON WA, HANFT J, NORWOOD P et al.; DERMAGRAFT DIABETIC FOOT ULCER STUDY GROUP: The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care (2003) 26(6):1701-1705.
71. VEVES A, FALANGA V, ARMSTRONG DG et al.: Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care (2001) 24(2):290-295.
72. LIPKIN S, CHAIKOF E, ISSEROFF Z, SILVERSTEIN P: Effectiveness of bilayered cellular matrix in healing of neuropathic diabetic foot ulcers: results of a multicenter pilot trial. Wounds (2003) 15(7):230-236.
73. APOPHARMA: Dermal living skin replacement. Investigators brochure: (2005) edition number 2.0, release date 05/04/2005.
74. DINI V, ROMANELLI M, PIAGGESI A, STEFANI A, MOSCA F: Cutaneous tissue engineering and lower extremity wounds (part 2). Int. J. Low Extrem. Wounds (2006) 5(1):27-34.
75. MARTIN BR, SANGALANG M, WU S, ARMSTRONG DG: Outcomes of allogenic acellular matrix therapy in treatment of diabetic foot wounds: an initial experience. Int. Wound J. (2005) 2(2):161-165.
76. NIEZGODA JA, VAN GILS, CC, FRYKBERG RG, HODDE JP: Randomized clinical trial comparing OASIS wound matrix to Regranex gel for diabetic ulcers. Adv. Skin Wound Care (2005) 18(5):258-266.
77. EDMONDS M, BATES M, DOXFORD M et al.: New treatments in ulcer healing and wound infection. Diabetes Metab. Res. Rev. (2000) 16(Suppl. 1):S51-S54.
78. VAZQUEZ JR, SHORT B, FINDLOW AH, NIXON BP, BOULTON AJ, ARMSTRONG DG: Outcomes of hyaluronan therapy in diabetic foot wounds. Diabetes Res. Clin. Pract. (2003) 59(2):123-127.
79. CARAVAGGI C, DE GIGLIO R, PRITELLI C et al.: HYAFF 11-based autologous dermal and epidermal grafts in the treatment of noninfected diabetic plantar and dorsal foot ulcers: a prospective, multicenter, controlled, randomized clinical trial. Diabetes Care. (2003) 26(10):2853-2859.
80. SO. MARSTON WA, USALA A, HILL RS, MENDES R, MINSLEY MA: Initial report of the use of an injectable porcine collagen-derived matrix to stimulate healing of diabetic foot wounds in humans. Wound Repair Regen. (2005) 13(3):243-247.
81. DI MARIO C, OSSINO AM, TREFILETTI M, POLOSA P, BERGHE F: Lyophilized collagen in the treatment of diabetic ulcers. Drugs Exf. Clin. Res. (1991) 17:371-373.
82. JIMENEZ PA, JIMENEZ SY: Tissue and cellular approaches to wound repair. Am. J. Surg. (2004) 187:56S-64S.
83. BADIAVAS EV, FALANGA V: Treatment of chronic wounds with bone marrow-derived cells. Arch. Dermatol. (2003) 139:510-516.
84. BARTSCH T, BREHM M, FALKE T, KOGLER G, WERNET P, STRAUER BE: Rapid healing of a therapy-refractory diabetic foot after transplantation of autologous bone marrow stem cells. Med. Klin. (Munich) (2005) 100(10):676-680.
85. YANG XF, WU YX, WANG HM et al.: Autologous peripheral blood stem cells transplantation in treatment of 62 cases of lower extremity ischemic disorder. Zhonghua Nei Ke Za Zhi. (2005) 44(2):95-98.
86. DAVIDSON JM: New and alternative treatments for the diabetic foot: stem cells and gene transfer. In: The Foot in Diabetes, Fourth edition. Boulton AJM, Cavanagh PR, Rayman G (Eds), Wiley & Sons, Chichester, UK (2006).
87. MAN LX, PARK JC, TERRY MJ et al.: Lentiviral gene therapy with platelet-derived growth factor B sustains accelerated healing of diabetic wounds over time. Ann. Plast. Surg. (2005) 55:81-86.
88. CHIN GA, THIGPIN TG, PERRIN KJ, MOLDAWER LL, SCHULTZ GS: Treatment of chronic ulcers in diabetic patients wich a topical metalloproteinase inhibitor, doxycycline. Wounds (2003) 15:315-323.
89. VEVES A, SHEEHAN P, PHAM HT: A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) versus standard treatment in the management of diabetic foot ulcers. Arch. Surg. (2002) 137(7):822-827.
90. VAN DEN BERG AJ, HALKES SB, VAN UFFORD HC, HOEKSTRA MJ, BEUKELMAN CJ: A novel formulation of metal tons and citric acid reduces reactive oxygen species in vitro. J. Wound Care (2003) 12:413-418.
91. LUO J, CHEN AF: Nitric oxide: a newly discovered function on wound healing. Acta Pharmacol. Sin. (2005) 26:259-264.
92. WITTE MB, KIYAMA T, BARBUL A: Nitric oxide enhances experimental wound healing in diabetes. Br. J. Surg. (2002) 89:1594-1601.
93. MABLEY J, SORIANO F, PACHER P et al.: The adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5′-N-methyl uronamide, is protective in two murine models of colitis. Eur. J. Pharmacol. (2003) 466(3):323-329.
94. APELQVIST J, CASTENFORS J, LARSSON J, STENSTROM A, PERSSON G: Ketanserin in the treatment of diabetic foot ulcer with severe peripheral vascular disease. Int. Angiol. (1990) 9:120-124.
95. MARTINEZ-DE JESUS FR, MORALES-GUZMAN M, CASTAÑEDA M, PEREZ-MORALES A, GARCIA-ALONSO J, MENDIOLA-SEGURA I: Randomized single-blind trial of topical ketanserin for healing acceleration of diabetic foot ulcers. Arch. Med. Res. (1997) 28(1):95-99.
96. ENGELMAYER J, BLEZINGER P, VARADHACHARY A: Talactoferrin induces key chemokines and cytokines in promoting wound healing in animal and Phase II human trails. Wound Repair Regen. (2006) 14(2):A59.
97. KALANI M, APELQVIST J, BLOMBÄCK M et al.: Effect of dalteparin on healing of chronic foot ulcers in diabetic patients with peripheral arterial occlusive disease. Diabetes Care (2003) 26:2575-2580.
98. KOBLIK T, SIERADZKI, J, SENDUR R et al.: The effect of insulin and sulodexide (Vessel Due F) on diabetic foot syndrome: pilot study in elderly patients. J. Diabetes Comp. (2001) 15(2):69-74.
99. BROCK FE, ABRI O, BAITSCH G et al.: Iloprost in the treatment of ischemic tissue lesions in diabetics. Results of a placebo-controlled multicenter study with a stable prostacyclin derivative. Schweiz. Med. Wochenschr. (1990) 120:1477-1482.
100. MULDER GD, PATT L, SANDERS L et al.: Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-L-histidyl-L-lysine copper. Wound Repair Regen. (1994) 2:259.
101. WU SC, CREWS RT, ARMSTRONG DG: The pivotal role of offloading in the management of neuropathic foot ulceration. Curr. Diab. Rep. (2005) 5(6):423-429.
102. LOOT MA, KENTER SB, AU FL et al.: Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-I, bFGF and PDGF-AB compared to controls. Eur. J. Cell Biol. (2002) 81(3):153-160.
103. SWEIZER SM, FANN SA, BORG TK, BAYNES JW, YOST MJ: What is the future of diabetic wound care? Diabetes Edu. (2006) 32(2):197-210.
104. SHEEHAN P, JONES P, CASELLI A, GIURINI JM, VEVES A: Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Diabetes Care (2003) 26(6):1879-1882.
105. SIBBALD RG, TORRANCE G, HUX M, ATTARD C, MILKOVICH N: Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers. Ostomy/Wound Management (2003) 49:76-84.
106. ALLENET B, PAREE F, LEBRUN T et al.: Cost-effectiveness modeling of dermagraft for the treatment of diabetic foot ulcers in the french context. Diabetes Metab. (2000) 26:125-132.